ReviewCardio-oncology (London, England)2026
The impact of cardiac amyloidosis on patients with multiple myeloma: a systematic review and meta-analysis.
Review in Cardio-oncology (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Cardiovascular Care in Multiple Myeloma: A Comprehensive Review and Integrated Systems-Based Approach from a UK Cardio-Oncology Centre of Excellence.Current cardiology reports · 2026Review
- Emerging Mechanisms and Therapeutic Strategies in Dilated Cardiomyopathy.Biomedicines · 2026Review
- Cardiovascular Mortality in Amyloidosis: Long-Term Trends, Disparities, and Projections in the United States.Risk management and healthcare policy · 2026Article
- Cardiac amyloidosis risk across ethnoracial and clinical subgroups: a five-year national study.American journal of cardiovascular disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundImmunoglobulin light chain (AL) amyloidosis is a well-recognized complication of multiple myeloma (MM), with important prognostic implications. However, the effect of cardiac AL amyloidosis on survival in MM patients has been rarely investigated.
objectiveWe aimed to perform a systematic review and meta-analysis to quantitatively assess the prognosis of MM patients with and without concomitant cardiac AL amyloidosis.
methodsWe searched PubMed, Scopus and Cochrane databases for studies comparing the survival of MM patients with and without concomitant cardiac AL amyloidosis. The primary outcome was all-cause mortality at 12 months (short-term), while secondary outcomes included all-cause mortality at 24 and 36 months (long-term). We also reconstructed individual patient data (IPD) from Kaplan–Meier curves to estimate Restricted Mean Survival Time (RMST). We pooled risk ratios (RR) with 95% confidence intervals (CI) using a random-effects model.
resultsWe included five studies encompassing 272 patients, of whom 110 (40%) presented MM with concomitant cardiac AL amyloidosis. All-cause mortality at 12 months was nearly five times higher in MM patients with cardiac involvement compared to those without cardiac involvement (RR 4.25; 95% CI 1.99–9.04; p = 0.0002). This trend remained consistent at long-term follow-up, with increased mortality observed in patients with cardiac involvement at 24 months (RR 1.84; 95% CI 1.19–2.84; p = 0.006) and 36 months (RR 1.78; 95% CI 1.26–2.52; p = 0.001. RMST was 27.28 months shorter in patients with cardiac involvement (p < 0.0001).
conclusionThese finding show that Cardiac AL amyloidosis is a major determinant of survival in MM patients. These findings should be interpreted in the context of the moderate risk of bias and heterogeneity of the available observational evidence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.